|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cui L, Li Y, Lv X, Li J, Wang X, Lei Z and
Li X: Expression of MicroRNA-301a and its functional roles in
malignant melanoma. Cell Physiol Biochem. 40:230–244. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mahgoub T, Eustace AJ, Collins DM, Walsh
N, O'Donovan N and Crown J: Kinase inhibitor screening identifies
CDK4 as a potential therapeutic target for melanoma. Int J Oncol.
47:900–908. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finn L, Markovic SN and Joseph RW: Therapy
for metastatic melanoma: The past, present, and future. BMC Med.
10:232012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carpinteiro A, Beckmann N, Seitz A,
Hessler G, Wilker B, Soddemann M, Helfrich I, Edelmann B, Gulbins E
and Becker KA: Role of acid sphingomyelinase-induced signaling in
melanoma cells for hematogenous tumor metastasis. Cell Physiol
Biochem. 38:1–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pagani E, Ruffini F, Antonini Cappellini
GC, Scoppola A, Fortes C, Marchetti P, Graziani G, D'Atri S and
Lacal PM: Placenta growth factor and neuropilin-1 collaborate in
promoting melanoma aggressiveness. Int J Oncol. 48:1581–1589. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Houghton AN and Polsky D: Focus on
melanoma. Cancer Cell. 2:275–278. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Caporali S, Alvino E, Lacal PM, Levati L,
Giurato G, Memoli D, Caprini E, Antonini Cappellini GC and D'Atri
S: Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating
effect of dabrafenib on the invasive behavior of melanoma cells
with acquired resistance to the BRAF inhibitor. Int J Oncol.
49:1164–1174. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
David CJ, Chen M, Assanah M, Canoll P and
Manley JL: HnRNP proteins controlled by c-Myc deregulate pyruvate
kinase mRNA splicing in cancer. Nature. 463:364–368. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Shao J, Zhu L, Zhao R, Xing J,
Wang J, Guo X, Tu S, Han B and Yu K: Molecular profiling identifies
prognostic markers of stage IA lung adenocarcinoma. Oncotarget.
8:74846–74855. 2017.PubMed/NCBI
|
|
11
|
Alaterre E, Raimbault S, Goldschmidt H,
Bouhya S, Requirand G, Robert N, Boireau S, Seckinger, Hose D,
Klein B and Moreaux J: CD24, CD27, CD36 and CD302 gene expression
for outcome prediction in patients with multiple myeloma.
Oncotarget. 8:98931–98944. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kelemen O, Convertini P, Zhang Z, Wen Y,
Shen M, Falaleeva M and Stamm S: Function of alternative splicing.
Gene. 344:1–20. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iqbal SM, Andavan GS and Lemmens-Gruber R:
Differential modulation of fast inactivation in cardiac sodium
channel splice variants by Fyn tyrosine kinase. Cell Physiol
Biochem. 37:825–837. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Avin BA, Umbricht CB and Zeiger MA: Human
telomerase reverse transcriptase regulation by DNA methylation,
transcription factor binding and alternative splicing (Review). Int
J Oncol. 49:2199–2205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonomi S, Gallo S, Catillo M, Pignataro D,
Biamonti G and Ghigna C: Oncogenic alternative splicing switches:
Role in cancer progression and prospects for therapy. Int J Cell
Biol. 2013:9620382013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fackenthal JD and Godley LA: Aberrant RNA
splicing and its functional consequences in cancer cells. Dis Model
Mech. 1:37–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Q, Gao J and Li Z: Identification of a
novel alternative splicing transcript variant of the suppressor of
fused: Relationship with lymph node metastasis in pancreatic ductal
adenocarcinoma. Int J Oncol. 49:2611–2619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Izaguirre DI, Zhu W, Hai T, Cheung HC,
Krahe R and Cote GJ: PTBP1-dependent regulation of USP5 alternative
RNA splicing plays a role in glioblastoma tumorigenesis. Mol
Carcinog. 51:895–906. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dhir A and Buratti E: Alternative
splicing: Role of pseudoexons in human disease and potential
therapeutic strategies. FEBS J. 277:841–855. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karni R, de Stanchina E, Lowe SW, Sinha R,
Mu D and Krainer AR: The gene encoding the splicing factor SF2/ASF
is a proto-oncogene. Nat Struct Mol Biol. 14:185–193. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z
and He J: Prognostic alternative mRNA splicing signature in
non-small cell lung cancer. Cancer Lett. 393:40–51. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu J, Chen Z and Yong L: Systematic
profiling of alternative splicing signature reveals prognostic
predictor for ovarian cancer. Gynecol Oncol. 148:368–374. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Suo C, Hrydziuszko O, Lee D, Pramana S,
Saputra D, Joshi H, Calza S and Pawitan Y: Integration of somatic
mutation, expression and functional data reveals potential driver
genes predictive of breast cancer survival. Bioinformatics.
31:2607–2613. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pal S, Bi Y, Macyszyn L, Showe LC,
O'Rourke DM and Davuluri RV: Isoform-level gene signature improves
prognostic stratification and accurately classifies glioblastoma
subtypes. Nucleic Acids Res. 42:e642014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Robertson AG, Shih J, Yau C, Gibb EA, Oba
J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, et al:
Integrative analysis identifies four molecular and clinical subsets
in uveal melanoma. Cancer Cell. 32:204–220.e15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ryan MC, Cleland J, Kim R, Wong WC and
Weinstein JN: SpliceSeq: A resource for analysis and visualization
of RNA-Seq data on alternative splicing and its functional impacts.
Bioinformatics. 28:2385–2387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lex A, Gehlenborg N, Strobelt H, Vuillemot
R and Pfister H: UpSet: Visualization of intersecting sets. IEEE
Trans Vis Comput Graph. 20:1983–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu G, Feng X and Stein L: A human
functional protein interaction network and its application to
cancer data analysis. Genome Biol. 11:R532010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu X, Si W, Liu X, He L, Ren J, Yang Z,
Yang J, Li W, Liu S, Pei F, et al: JMJD6 promotes melanoma
carcinogenesis through regulation of the alternative splicing of
PAK1, a key MAPK signaling component. Mol Cancer. 16:1752017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang P, Feng S, Liu G, Wang H, Fu A, Zhu
H, Ren Q, Wang B, Xu X, Bai H and Dong C: CD82 suppresses CD44
alternative splicing-dependent melanoma metastasis by mediating
U2AF2 ubiquitination and degradation. Oncogene. 35:5056–5069. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Furney SJ, Pedersen M, Gentien D, Dumont
AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la
Grange P, Roman-Roman S, et al: SF3B1 mutations are associated with
alternative splicing in uveal melanoma. Cancer Discov. 3:1122–1129.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Quesada V, Conde L, Villamor N, Ordóñez
GR, Jares P, Bassaganyas L, Ramsay AJ, Beà S, Pinyol M,
Martínez-Trillos A, et al: Exome sequencing identifies recurrent
mutations of the splicing factor SF3B1 gene in chronic lymphocytic
leukemia. Nat Genet. 44:47–52. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al: Pancreatic cancer genomes reveal aberrations in axon
guidance pathway genes. Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan Q, Shai O, Lee LJ, Frey BJ and
Blencowe BJ: Deep surveying of alternative splicing complexity in
the human transcriptome by high-throughput sequencing. Nat Genet.
40:1413–1415. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Baty F, Klingbiel D, Zappa F and Brutsche
M: High-throughput alternative splicing detection using dually
constrained correspondence analysis (DCCA). J Biomed Inform.
58:175–185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oltean S and Bates DO: Hallmarks of
alternative splicing in cancer. Oncogene. 33:5311–5318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Das S and Krainer AR: Emerging functions
of SRSF1, splicing factor and oncoprotein, in RNA metabolism and
cancer. Mol Cancer Res. 12:1195–1204. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Díaz R, Peña C, Silva J, Lorenzo Y, García
V, García JM, Sánchez A, Espinosa P, Yuste R, Bonilla F and
Domínguez G: p73 isoforms affect VEGF, VEGF165b and PEDF expression
in human colorectal tumours. VEGF165b downregulation as a marker
for poor prognosis. Int J Cancer. 123:1060–1067. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bates DO, Cui TG, Doughty JM, Winkler M,
Sugiono M, Shields JD, Peat D, Gillatt D and Harper SJ: VEGF165b,
an inhibitory splice variant of vascular endothelial growth factor,
is down-regulated in renal cell carcinoma. Cancer Res.
62:4123–4131. 2002.PubMed/NCBI
|
